Okada Tsuneji, Kanai Toru, Tachikawa Noriko, Munakata Motohiro, Kasugai Shohei
*Lecturer, Clinic for Implant Dentistry, Dental Hospital, Tokyo Medical and Dental University, Tokyo, Japan. †Assistant Professor, Clinic for Implant Dentistry, Dental Hospital, Tokyo Medical and Dental University, Tokyo, Japan. ‡Assistant Professor, Department of Oral and Maxillofacial Rehabilitation, Removable Prosthetics, Kanagawa Dental University, Kanagawa, Japan. §Professor, Clinic for Implant Dentistry, Dental Hospital, Tokyo Medical and Dental University, Tokyo, Japan.
Implant Dent. 2017 Apr;26(2):275-283. doi: 10.1097/ID.0000000000000577.
We have recently used highly pure β-TCP (beta-tricalcium phosphate) as the bone grafting material to avoid highly invasive autogenous bone grafting. We evaluated the osseoconduction potential of highly pure β-TCP in sinus augmentation surgery treatment.
The study group comprised 13 patients who underwent maxillary sinus floor augmentation with β-TCP alone. Seven patients underwent sinus augmentation and implant placement simultaneously. Six patients were treated with a staged approach. Six months after surgery, specimens were obtained from 7 patients (for lateral biopsy) and 6 patients (for vertical biopsy).
Histological and histomorphometrical analysis showed a mean bone proportion of 30.8% (vertical) and 12.0% (lateral) for new bone formation and good integration of the β-TCP. New bone formation was lower in the lateral biopsy specimens than in the vertical.
Highly pure β-TCP is a safe bone-grafting material with superior osteoconductive properties. Histologic and radiographic examinations indicate that β-TCP is slowly resorbed, which results in unresorbed graft material remaining even 6 months after the procedure, and that new bone replacement occurs slowly for approximately 1 year.
我们最近使用高纯度β-磷酸三钙(β-TCP)作为骨移植材料,以避免高侵入性的自体骨移植。我们评估了高纯度β-TCP在鼻窦增高手术治疗中的骨传导潜力。
研究组包括13例仅使用β-TCP进行上颌窦底增高术的患者。7例患者同时进行了鼻窦增高和种植体植入。6例患者采用分期治疗方法。术后6个月,从7例患者(用于横向活检)和6例患者(用于纵向活检)获取标本。
组织学和组织形态计量学分析显示,新骨形成的平均骨比例为30.8%(纵向)和12.0%(横向),且β-TCP融合良好。横向活检标本中的新骨形成低于纵向活检标本。
高纯度β-TCP是一种安全的骨移植材料,具有优异的骨传导性能。组织学和影像学检查表明,β-TCP吸收缓慢,这导致即使在手术后6个月仍有未吸收的移植材料残留,并且新骨替代大约在1年内缓慢发生。